Neith Corporation
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company offers nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also provides genetic testing services. In addition, the company offers energy and dual-purpose m… Read more
Neith Corporation (6236) - Net Assets
Latest net assets as of September 2025: NT$154.76 Million TWD
Based on the latest financial reports, Neith Corporation (6236) has net assets worth NT$154.76 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$168.17 Million) and total liabilities (NT$13.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$154.76 Million |
| % of Total Assets | 92.03% |
| Annual Growth Rate | 29.12% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 96.57 |
Neith Corporation - Net Assets Trend (2021–2024)
This chart illustrates how Neith Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neith Corporation (2021–2024)
The table below shows the annual net assets of Neith Corporation from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$154.32 Million | -11.68% |
| 2023-12-31 | NT$174.72 Million | -16.20% |
| 2022-12-31 | NT$208.49 Million | +190.89% |
| 2021-12-31 | NT$71.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neith Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2060500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$416.56 Million | 269.94% |
| Total Equity | NT$154.32 Million | 100.00% |
Neith Corporation Competitors by Market Cap
The table below lists competitors of Neith Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UJOGF
OTCQB:UJOGF
|
$3.26 Million |
|
Petrol d.d.
LSE:0M0P
|
$3.26 Million |
|
Predilife
PA:ALPRE
|
$3.26 Million |
|
11880 Solutions AG
XETRA:TGT
|
$3.26 Million |
|
Kubera Gold Corp.
V:KBRA
|
$3.26 Million |
|
SAMSUNG EPISHOLDINGS CO LTD
KO:0126Z0
|
$3.26 Million |
|
Polaris Investama Tbk
JK:PLAS
|
$3.26 Million |
|
Cell Impact AB
ST:CI
|
$3.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neith Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 174,720,000 to 154,319,000, a change of -20,401,000 (-11.7%).
- Net loss of 16,884,000 reduced equity.
- Other factors decreased equity by 3,517,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-16.88 Million | -10.94% |
| Other Changes | NT$-3.52 Million | -2.28% |
| Total Change | NT$- | -11.68% |
Book Value vs Market Value Analysis
This analysis compares Neith Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.54x to 5.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$2.26 | NT$21.60 | x |
| 2022-12-31 | NT$5.01 | NT$21.60 | x |
| 2023-12-31 | NT$4.19 | NT$21.60 | x |
| 2024-12-31 | NT$3.70 | NT$21.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neith Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -37.05%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.11x
- Recent ROE (-10.94%) is above the historical average (-13.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -7.47% | -17.05% | 0.41x | 1.07x | NT$-12.52 Million |
| 2022 | -11.36% | -73.89% | 0.14x | 1.10x | NT$-44.54 Million |
| 2023 | -22.91% | -100.33% | 0.21x | 1.10x | NT$-57.51 Million |
| 2024 | -10.94% | -37.05% | 0.27x | 1.11x | NT$-32.32 Million |
Industry Comparison
This section compares Neith Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neith Corporation (6236) | NT$154.76 Million | -7.47% | 0.09x | $3.26 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |